Natalizumab Fails In Stroke But A Phase III Study Of BIIB093 Beckons
Executive Summary
Biogen's MS therapy natalizumab may have been a disappointment in ischemic stroke, but the neuroscience-focused company is aiming to soon move another potential stroke therapy into late-stage clinical studies.